These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23258101)

  • 1. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
    Kim DY; Han KH
    Dig Dis; 2012; 30(6):598-602. PubMed ID: 23258101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
    Kim YH; Kim DY
    Oncology; 2013; 84 Suppl 1():34-9. PubMed ID: 23428856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
    Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
    Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
    Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?
    Jiang W; Zeng ZC
    Oncology; 2013; 84 Suppl 1():69-74. PubMed ID: 23428862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
    Minocha J; Salem R; Lewandowski RJ
    Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Survival benefit with intraarterial techniques in hepatocellular carcinoma].
    Sangro B
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 2():95-101. PubMed ID: 25087719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
    Fidelman N; Kerlan RK
    AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Eggert T; Greten TF
    Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of intermediate-stage hepatocellular carcinoma.
    Forner A; Gilabert M; Bruix J; Raoul JL
    Nat Rev Clin Oncol; 2014 Sep; 11(9):525-35. PubMed ID: 25091611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
    Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
    Lorenzin D; Pravisani R; Leo CA; Bugiantella W; Soardo G; Carnelutti A; Umberto B; Risaliti A
    Cancer Biother Radiopharm; 2016 Mar; 31(2):65-9. PubMed ID: 26986817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
    Takano M; Kokudo T; Miyazaki Y; Kageyama Y; Takahashi A; Amikura K; Sakamoto H
    World J Gastroenterol; 2016 Nov; 22(42):9445-9450. PubMed ID: 27895433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.